Innova Captab (NSE:INNOVACAP) Other Current Payables: ₹256 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:INNOVACAP Innova Captab Ltd NSE:INNOVACAP
48 GF Score
Price ₹944.50
! 6 Warning Signs
View Full Analysis

What is Innova Captab Other Current Payables?

Innova Captab NSE:INNOVACAP -1.00% 48 Other Current Payables is ₹256 Mil as of Mar. 2026. GuruFocus rates NSE:INNOVACAP with a GF Score™ of 48/100. The stock has 6 warning signs investors should review.

Innova Captab's Other Current Payables for the quarter that ended in Mar. 2026 was ₹256 Mil.

Innova Captab's quarterly Other Current Payables stayed the same from Sep. 2025 (₹0 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹256 Mil).

Innova Captab's annual Other Current Payables increased from Mar. 2024 (₹269 Mil) to Mar. 2025 (₹293 Mil) but then declined from Mar. 2025 (₹293 Mil) to Mar. 2026 (₹256 Mil).

Innova Captab Other Current Payables Related Terms

Innova Captab Other Current Payables Historical Data

* Premium members only.

The historical data trend for Innova Captab's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innova Captab Other Current Payables Chart

Innova Captab Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Payables
Get a 7-Day Free Trial 76.42 91.65 269.10 293.11 256.07

Innova Captab Quarterly Data
Mar19 Mar20 Mar21 Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 293.11 0.00 0.00 0.00 256.07
NSE:INNOVACAP
48GF Score
Innova Captab Ltd NSE:INNOVACAP
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Innova Captab Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of ₹256 Mil mean?
Innova Captab (NSE:INNOVACAP) has a Other Current Payables of ₹256 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Innova Captab and its competitors.
Is Innova Captab's Other Current Payables too high?
Innova Captab's current Other Current Payables is ₹256 Mil. Overall, Innova Captab has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Innova Captab's Other Current Payables compare to ZTS?
Innova Captab's Other Current Payables of ₹256 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Drug Manufacturers company?
A good Other Current Payables depends on the Drug Manufacturers industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Innova Captab and its competitors. Innova Captab's current Other Current Payables is ₹256 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innova Captab stock overvalued right now?
Innova Captab (NSE:INNOVACAP) has a current Other Current Payables of ₹256 Mil. The current Other Current Payables is ₹256 Mil. Innova Captab's overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Innova Captab (NSE:INNOVACAP), the current Other Current Payables is ₹256 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Innova Captab Business Description

Other Exchanges 544067:India
Address Plot No.320, Industrial Area, Phase-1, Panchkula, HR, IND, 134113
Innova Captab Ltd is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. The Company has identified "Drugs and pharmaceutical products" as single operating segment. The company has presence in India, and Outside India. The company generates majority of revenue from India. The company's products are Cephalosporins, Proton Pump Inhibitor, Antocholinergic and Heparin NSAIDs, Analgesics and Antipyretic, Anticold and Antiallergic, Antiemetic, Antidiabetic, Antispasmodic, Antifibrinolytic, Cardiovascular, Antioxidant and Vitamins, Antihyperuricemia and Antigout, Fluoroquinolone and Macrolide, Nootropics and Neurotonics/ Neurotrophics, Antiulcerative, Antimalarial Anxiolytic, Anticonvulsant and Antipsychotic, Bladder and Prostate Disorder, etc.
48GF Score

Get the complete analysis for NSE:INNOVACAP

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹944.50
Price